Tin tức & Cập nhật

In individuals with stable coronary artery disease (CAD), intensifying their lipid-lowering regimen with evolocumab, a PCSK9* inhibitor, led to improvements in coronary plaque characteristics on intravascular imaging, findings from the YELLOW III trial have shown.

For patients with stage III or IV melanoma, treatment with pembrolizumab both before and after surgical resection leads to longer event-free survival than treatment with pembrolizumab only after the procedure, according to the results of a phase II study.

Vitamin D may offer brain boosting benefits, with a large study providing evidence that vitamin D supplementation exerts some effect in the prevention of dementia.

Outpatient oritavancin therapy for patients with acute uncomplicated cellulitis results in a decrease in 30-day hospital readmissions or admissions when compared with inpatient standard of care (SoC), a recent study has shown.

The phase III STELLAR trial lives up to its name, delivering stellar results and offering hope for patients with pulmonary arterial hypertension (PAH), a rare, progressive, life-threatening disorder affecting the heart and lungs, by adding sotatercept – a novel first-in-class activin signalling inhibitor – to background therapy.